- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
BTX-A for overactive bladder tied to incomplete emptying and UTI risk: Study
USA: In a new study conducted by William Stuart Reynolds and team, it was found that incomplete emptying and urinary tract infection (UTI) were increased than earlier investigations in people who had Onabotulinumtoxin A (BTX-A) for overactive bladder (OAB). Men were especially vulnerable to inadequate emptying. The findings of this study were published in Neurourology and Urodynamics Journal on 12th January 2022.
Although BTX-A is an effective treatment for OAB, patients may be put off by side effects. The goal of the study was to report real-world rates of incomplete emptying and urinary tract infection in men and women who had BTX-A for OAB.
For this study, in 2016, eleven clinical sites conducted a retrospective analysis of adults who received their first BTX-A injection (100 units) for idiopathic OAB. Post Void residual (PVR) > 150 ml, prior BTX-A, pelvic radiotherapy, or the need for pre-procedure catheterization were all excluded. At 6 months, the primary outcomes were incomplete emptying (clean intermittent catheterization [CIC] or PVR 300 ml without the need for CIC) and urinary tract infection (UTI) (symptoms with either positive culture or urinalysis or empiric treatment). Using univariate and multivariate models, we examined rates of incomplete emptying and UTI between and across sexes.
The results of this study stated as follow:
1. 278 patients (48 men and 230 women) met the eligibility requirements. The average age was 65.5 years (range: 24-95).
2. Incomplete emptying was seen in 35% of males and 17% of women.
3. Incomplete emptying was found to be 2.4 times more often in men than in women.
4. 17% of men and 23.5 percent of women experienced at least one UTI, with the majority occurring during the first month after injection.
5. A history of past UTI was the best predictor of UTI (OR: 4.2).
"Rates of incomplete emptying and UTI were higher than many previously published studies in this multicenter retrospective study," wrote the authors. "Men were at particular risk for incomplete emptying. Prior UTI was the primary risk factor for postprocedure UTI."
Reference:
Reynolds WS, Suskind AM, Anger JT, Brucker BM, Cameron AP, Chung DE, Daignault-Newton S, Lane GI, Lucioni A, Mourtzinos AP, Padmanabhan P, Reyblat PX, Smith AL, Tenggardjaja CF, Lee UJ; SUFU Research Network. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022 Jan 12. doi:10.1002/nau.24871. Epub ahead of print. PMID: 35019167.
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751